Immunomodulating IL-6 activity by murine monoclonal antibodies

Area of Science:

• Immunology
• Oncology

Background:

• Human anti-mouse immunoglobulin antibody (HAMA) responses are common with murine monoclonal antibody (MAb) therapies.
• Interleukin-6 (IL-6) plays a role in C-reactive protein (CRP) production and is a target for cancer treatment.

Purpose of the Study:

• To analyze the HAMA response in patients treated with B-E8, an anti-IL-6 MAb.
• To determine the impact of HAMA on B-E8 MAb pharmacokinetics and treatment efficacy in multiple myeloma (MM) and metastatic renal cell carcinoma (MRCC) patients.

Main Methods:

• Assessed HAMA development in 12 patients (6 MM, 6 MRCC) receiving B-E8 MAb.
• Monitored serum CRP levels as an indicator of IL-6 inhibition.
• Characterized HAMA specificity (anti-idiotype, anti-isotype) and its effect on B-E8 levels and function.

Main Results:

• Nine patients developed HAMA, including anti-idiotype antibodies.
• Two patients with anti-isotype HAMA experienced rapid B-E8 clearance and loss of treatment efficacy.
• Patients with only anti-idiotype HAMA maintained B-E8 levels and IL-6 inhibition, with MAb retaining binding and inhibitory functions.

Conclusions:

• HAMA against anti-IL-6 MAb idiotopes does not necessarily lead to MAb clearance or functional loss.
• Unlike HAMA against cell-targeting MAbs, anti-idiotype HAMA against anti-IL-6 MAbs did not compromise treatment efficacy in most patients.
• The specificity of the HAMA response is critical in determining its clinical impact on MAb therapy.